Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on May 8)

• CONMED Corporation CNMD
• Enanta Pharmaceuticals Inc ENTA
• Helius Medical Technologies Inc HSDT
• SurModics, Inc. SRDX

Down In The Dumps

(Stocks hitting 52-week lows on May 8)

• Acasti Pharma Inc ACST
• Agenus Inc AGEN (has been falling since it reported Q1 results on Monday)
• Alimera Sciences Inc ALIM
• Aralez Pharmaceuticals Inc ARLZ (reported Q1 results Tuesday and announced plans to discontinue U.S. commercial business)
• Celgene Corporation CELG
• DENTSPLY SIRONA Inc XRAY
• Regeneron Pharmaceuticals Inc REGN
• RXi Pharmaceuticals Corp RXII
• VBI Vaccines Inc VBIV

Medical/Healthcare/Biotech Conferences

• 2018 Disruptive Growth and Healthcare Conference – May 8-9, in New York City
• Deutsche Bank 43rd Annual Health Care Conference – May 8-9, at the InterContinental Boston Hotel

See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Stocks In Focus

Opko Posts Better-than-expected results

Opko Health Inc. OPK reported a narrower-than-expected Q1 loss of 8 cents per share on above-consensus revenues of $254.9 million.

The stock rallied 6.21 percent to $3.42 in after-hours trading.

Penumbra's Beat-And-Raise Quarter

Penumbra Inc PEN swung to a profit in Q1 and reported above-consensus revenues. The company also raised FY18 revenue guidance.

The stock rallied 5.96 percent to $144 after hours.

Synthetic Biologic Posts Narrower-Than-Expected Loss

Synthetic Biologics Inc SYN reported a loss of 2 cents per share for its Q1, narrower than the loss of 5 cents expected.

The stock jumped 11.28 percent to $0.2773 in after-hours trading.

OpGen Q1 Beats Estimates

OpGen Inc OPGN reported a narrower-than-expected loss and above-consensus revenues for its Q1.

The stock gained 3.68 percent to $1.97 in after-hours trading.

Transenterix Gains On Q1 Beat

Transenterix Inc TRXC shares were up 12 percent Wednesday morning in reaction to its Q1 results that showed break-even bottom-line results and revenues of $4.8 million. Analysts, on average, estimated a loss of 7 cents per share on revenues of $3.84 million.

On The Radar

The following companies report earnings on Wednesday:

• Mylan NV MYL Q1 EPS $0.96 Misses $0.98 Estimate, Sales $2.68B Miss $2.75B Estimate
• Endocyte, Inc. ECYT
• FibroGen Inc FGEN
• Jounce Therapeutics Inc JNCE Q1 EPS $(0.40) Misses $(0.31) Estimate, Sales $11.19M Miss $15.64M Estimate
• Neos Therapeutics Inc NEOS Q1 EPS $(0.50) Misses $(0.48) Estimate, Sales $10.72M Beat $9.79M Estimate
• AcelRx Pharmaceuticals Inc ACRX
• Adaptimmune Therapeutics PLC – ADR ADAP Q3 EPS $(0.04) Beats $(0.24) Estimate, Sales $8.19M Miss $9.1M Estimate
• Arcadia Biosciences Inc RKDA
• Array Biopharma Inc ARRY
• Audentes Therapeutics Inc BOLD
• Collegium Pharmaceutical Inc COLL
• Glaukos Corp GKOS
• Horizon Pharma PLC HZNP Q1 EPS $0.03 Misses $0.07 Estimate, Sales $223.881M Miss $234.17M Estimate
• Inovio Pharmaceuticals Inc INO
• Portola Pharmaceuticals Inc PTLA
• PTC Therapeutics, Inc. PTCT
• Puma Biotechnology Inc PBYI
• Viking Therapeutics Inc VKTX
• Ophthotech Corp OPHT Q1 EPS $(0.36) Beats $(0.40) Estimate
• Novavax, Inc. NVAX